{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T09:41:58Z","timestamp":1772530918025,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adjuvant immunotherapy is revolutionising care for patients with resected stage III and IV melanoma. However, immunotherapy may be associated with toxicity, making treatment decisions complicated. This study aimed to identify factors physicians and nurses considered regarding adjuvant immunotherapy for melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In-depth interviews were conducted with physicians (medical oncologists, surgeons and dermatologists) and nurses managing patients with resected stage III melanoma at three Australian tertiary melanoma centres between July 2019 and March 2020. Factors considered regarding adjuvant immunotherapy were explored. Recruitment continued until data saturation and thematic analysis was undertaken.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-five physicians and nurses, aged 28\u201368\u2009years, 60% females, including eleven (44%) medical oncologists, eight (32%) surgeons, five (20%) nurses, and one (4%) dermatologist were interviewed. Over half the sample managed five or more new resected stage III patients per month who could be eligible for adjuvant immunotherapy. Three themes about adjuvant immunotherapy recommendations emerged: [1] clinical and patient factors, [2] treatment information provision, and [3] individual physician\/nurse factors. Melanoma sub-stage and an individual patient\u2019s therapy risk\/benefit profile were primary considerations. Secondary factors included uncertainty about adjuvant immunotherapy\u2019s effectiveness and their views about treatment burden patients might consider acceptable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients\u2019 disease sub-stage and their treatment risk versus benefit drove the melanoma health care professionals\u2019 adjuvant immunotherapy endorsement. Findings clarify clinician preferences and values, aiding clinical communication with patients and facilitating clinical decision-making about management options for resected stage III melanoma.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-08752-1","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T14:02:31Z","timestamp":1631282551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6836-0382","authenticated-orcid":false,"given":"Ann","family":"Livingstone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-0857","authenticated-orcid":false,"given":"Kathy","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-7562","authenticated-orcid":false,"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-0572","authenticated-orcid":false,"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"issue":"6","key":"8752_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"8752_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"N Engl J Med"},{"issue":"19","key":"8752_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"issue":"6","key":"8752_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin"},{"key":"8752_CR5","unstructured":"Australian Government. Pharmaceutical Benefits Scheme - Nivolumab [Webpage]. Australian Government; 2020 [20 August 2020]. Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/10745M-10748Q-10764M-10775D-11143L-11150W-11152Y-11153B-11157F-11158G-11159H-11160J-11411N-11425H-11434T-11435W-11532Y-11543M-11626X-11627Y-11631E-11635J-11636K-11642R-11900H-11906P."},{"key":"8752_CR6","unstructured":"Australian Government. Pharmaceutical Benefits Scheme - Pembrolizumab [Webpage]. Australian Government; 2020 [10 September 2020]. Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/10424P-10436G-10475H-10493G-11330H-11352L-11492W-11494Y-11632F-11646Y-12119W-12120X-12121Y-12122B-12123C-12124D-12125E-12126F-12127G-12128H-12129J-12130K."},{"key":"8752_CR7","unstructured":"US Federal Drug Administration. Medication guide Opdivo Nivolumab injection 2019 [8 October 2019]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125554s075lbl.pdf#page=75."},{"key":"8752_CR8","unstructured":"European Medicines Agency. Human Medicine European public assessment report Opdivo (nivolumab) 2019 [8 October 2019]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo"},{"issue":"2","key":"8752_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1245\/s10434-019-07963-y","volume":"27","author":"A Livingstone","year":"2020","unstructured":"Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for immunotherapy in melanoma: a systematic review. Ann Surg Oncol. 2020;27(2):571\u201384. https:\/\/doi.org\/10.1245\/s10434-019-07963-y.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"8752_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40271-021-00507-1","volume":"14","author":"A Livingstone","year":"2021","unstructured":"Livingstone A, Milne D, Dempsey K, Muscat DM, Menzies AM, Howard K, et al. Should I have adjuvant immunotherapy? An interview study among adults with resected stage 3 melanoma and their partners. Patient. 2021;14(5):635\u201347. https:\/\/doi.org\/10.1007\/s40271-021-00507-1.","journal-title":"Patient"},{"key":"8752_CR11","volume-title":"Designing and conducting mixed method research","author":"JW Cresswell","year":"2011","unstructured":"Cresswell JW, Plano Clark VL. Designing and conducting mixed method research. 2nd ed. Thousand Oaks: SAGE; 2011.","edition":"2"},{"issue":"20","key":"8752_CR12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"key":"8752_CR13","volume-title":"Qualitative Research Methods","author":"M Hennink","year":"2020","unstructured":"Hennink M, Hutter I, Bailey A. Qualitative Research Methods. London: SAGE; 2020."},{"issue":"6","key":"8752_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1177\/0272989X08327069","volume":"28","author":"VF Reyna","year":"2008","unstructured":"Reyna VF. Theories of medical decision making and health: an evidence-based approach. Med Decis Mak. 2008;28(6):829\u201333. https:\/\/doi.org\/10.1177\/0272989X08327069.","journal-title":"Med Decis Mak"},{"key":"8752_CR15","doi-asserted-by":"crossref","DOI":"10.4135\/9781483398655","volume-title":"100 questions (and answers) about qualitative research","author":"LM Given","year":"2016","unstructured":"Given LM. 100 questions (and answers) about qualitative research. Thousand Oaks: Sage; 2016."},{"issue":"9","key":"8752_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351. https:\/\/doi.org\/10.1097\/ACM.0000000000000388.","journal-title":"Acad Med"},{"key":"8752_CR17","volume-title":"Qualitative inquiry and research design: choosing among five approaches","author":"JW Creswell","year":"2018","unstructured":"Creswell JW, Poth CN. Qualitative inquiry and research design: choosing among five approaches. 4th ed. SAGE: California; 2018.","edition":"4"},{"issue":"3","key":"8752_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2001.19.3.812","volume":"19","author":"KL Kilbridge","year":"2001","unstructured":"Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001;19(3):812\u201323. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.812.","journal-title":"J Clin Oncol"},{"issue":"11","key":"8752_CR19","doi-asserted-by":"publisher","first-page":"e111237","DOI":"10.1371\/journal.pone.0111237","volume":"9","author":"R Krammer","year":"2014","unstructured":"Krammer R, Heinzerling L. Therapy preferences in melanoma treatment: willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS One. 2014;9(11):e111237. https:\/\/doi.org\/10.1371\/journal.pone.0111237.","journal-title":"PLoS One"},{"issue":"1","key":"8752_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jval.2014.10.004","volume":"18","author":"J Arellano","year":"2015","unstructured":"Arellano J, Hauber AB, Mohamed AF, Gonzalez JM, Collins H, Hechmati G, et al. Physicians\u2019 preferences for bone metastases drug therapy in the United States. Value Health. 2015;18(1):78\u201383. https:\/\/doi.org\/10.1016\/j.jval.2014.10.004.","journal-title":"Value Health"},{"issue":"4","key":"8752_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/bjc.2014.322","volume":"111","author":"M Kunneman","year":"2014","unstructured":"Kunneman M, Pieterse AH, Stiggelbout AM, Nout RA, Kamps M, Lutgens LC, et al. Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians. Br J Cancer. 2014;111(4):674\u20139. https:\/\/doi.org\/10.1038\/bjc.2014.322.","journal-title":"Br J Cancer"},{"issue":"7","key":"8752_CR22","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/bmt.2010.225","volume":"46","author":"M Shafey","year":"2011","unstructured":"Shafey M, Lupichuk SM, Do T, Owen C, Stewart DA. Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplant. 2011;46(7):962\u20139. https:\/\/doi.org\/10.1038\/bmt.2010.225.","journal-title":"Bone Marrow Transplant"},{"key":"8752_CR23","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/PPA.S140226","volume":"11","author":"FX Liu","year":"2017","unstructured":"Liu FX, Witt EA, Ebbinghaus S, DiBonaventura BG, Shinde R, Basurto E, et al. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Prefer Adherence. 2017;11:1389\u201399. https:\/\/doi.org\/10.2147\/PPA.S140226.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"8752_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1089\/jpm.2019.0402","volume":"23","author":"L Traeger","year":"2020","unstructured":"Traeger L, Rapoport C, Wright E, El-Jawahri A, Greer JA, Park ER, et al. Nature of discussions about systemic therapy discontinuation or hospice among patients, families, and palliative care clinicians during Care for Incurable Cancer: a qualitative study. J Palliat Med. 2020;23(4):542\u20137. https:\/\/doi.org\/10.1089\/jpm.2019.0402.","journal-title":"J Palliat Med"},{"issue":"5","key":"8752_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/0277-9536(91)90288-N","volume":"32","author":"RL Street Jr","year":"1991","unstructured":"Street RL Jr. Information-giving in medical consultations: the influence of patients\u2019 communicative styles and personal characteristics. Soc Sci Med. 1991;32(5):541\u20138. https:\/\/doi.org\/10.1016\/0277-9536(91)90288-N.","journal-title":"Soc Sci Med"},{"issue":"1","key":"8752_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pec.2003.07.001","volume":"55","author":"PE Schofield","year":"2004","unstructured":"Schofield PE, Butow PN. Towards better communication in cancer care: a framework for developing evidence-based interventions. Patient Educ Couns. 2004;55(1):32\u20139. https:\/\/doi.org\/10.1016\/j.pec.2003.07.001.","journal-title":"Patient Educ Couns"},{"issue":"3","key":"8752_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1023\/A:1011100524076","volume":"12","author":"PE Schofield","year":"2001","unstructured":"Schofield PE, Beeney LJ, Thompson JF, Butow PN, Tattersall MH, Dunn SM. Hearing the bad news of a cancer diagnosis: the Australian melanoma patient\u2019s perspective. Ann Oncol. 2001;12(3):365\u201371. https:\/\/doi.org\/10.1023\/A:1011100524076.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08752-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:03:24Z","timestamp":1699463004000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08752-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8752"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08752-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Sydney Local Health District Human Research Ethics Committee (HREC\/18\/RPAH\/736) granted ethics approval. Participants provided informed written consent, with the Declaration of Helsinki underpinning this study [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as this manuscript does not reveal any identifiable participant information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL, KD, KH and RLM have no conflicts of interest to declare. MRS received institutional research support from Amgen, Astellas, AstraZeneca, Bayer, Bionomics, Bristol-Myers Squibb (BMS), Celgene, Medivation, Merck Sharpe & Dohme (MSD), Pfizer, Roche, Sanofi and Tilray, but does not sit on any advisory boards. AMM has served on advisory boards for BMS, MSD, Novartis, Pierre-Fabre, Qbiotics and Roche. GVL is a consultant advisor for Aduro Biotech, Amgen, Array Biopharma, Boehringer Ingelheim, BMS, Hexel AG, Highlight Therapeutics SL, MSD, Novartis, Pierre-Fabre, QBiotics, Regeneron Pharmaceuticals, SkylineDX B.V., and Specialised Therapeutics Australia. MSC has served on advisory boards for Amgen, BMS, Eisai, Ideaya, MSD, Nektar, Novartis, Oncosec, Pierre-Fabre, Qbiotics, Regeneron, Roche, and Sanofi, and received honoraria from BMS, MSD, and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1014"}}